Clinical Trial Update: Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing adjuvant erlotinib intercalating with chemotherapy versus adjuvant chemotherapy alone in NSCLC with common EGFR mutations has been wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adjuvant chemotherapy (unspecified regimen)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Yonsei University | Conditions: NSCLC | Phase 3 | Status: WITHDRAWN